BioCryst Pharmaceuticals logo

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 6.1%

Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price rose 6.1% during trading on Friday . The stock traded as high as $3.64 and last traded at $3.64. Approximately 6,961,500 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 7,646,306 shares. The stock had previously closed at $3.43.

BCRX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, August 7th. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 25th. BTIG Research initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 16th. They issued a “neutral” rating for the company. Finally, Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $7.71.

The company has a current ratio of 1.99, a quick ratio of 1.93 and a debt-to-equity ratio of 0.46. The company has a market cap of $642.70 million, a PE ratio of -4.33 and a beta of 2.63. The business’s 50-day simple moving average is $3.96 and its 200-day simple moving average is $3.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. BioCryst Pharmaceuticals had a negative net margin of 236.65% and a negative return on equity of 603.57%. The company had revenue of $2.87 million during the quarter, compared to the consensus estimate of $3.17 million. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.91 earnings per share for the current fiscal year.

In other BioCryst Pharmaceuticals news, CFO Anthony Doyle purchased 54,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average price of $4.08 per share, for a total transaction of $220,320.00. Following the purchase, the chief financial officer now directly owns 54,000 shares in the company, valued at approximately $220,320. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc increased its stake in shares of BioCryst Pharmaceuticals by 6.7% during the 1st quarter. Legal & General Group Plc now owns 41,327 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 2,602 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of BioCryst Pharmaceuticals by 13.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 25,550 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 3,000 shares during the last quarter. American International Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 3.6% during the 2nd quarter. American International Group Inc. now owns 94,339 shares of the biotechnology company’s stock worth $450,000 after purchasing an additional 3,300 shares during the last quarter. Point72 Hong Kong Ltd increased its stake in shares of BioCryst Pharmaceuticals by 160.5% during the 2nd quarter. Point72 Hong Kong Ltd now owns 7,184 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 4,426 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in BioCryst Pharmaceuticals by 2.5% in the 1st quarter. Rhumbline Advisers now owns 188,708 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 4,539 shares during the last quarter. Institutional investors own 75.15% of the company’s stock.

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Recommended Story: Can systematic risk be avoided?

Receive News & Ratings for BioCryst Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.